149 related articles for article (PubMed ID: 36879525)
1. Dose-finding based on feasibility and late-onset toxicity in adoptive cell therapy trials.
Bagley EM; Wages NA
J Biopharm Stat; 2024 Mar; 34(2):151-163. PubMed ID: 36879525
[TBL] [Abstract][Full Text] [Related]
2. Adaptive dose-finding based on safety and feasibility in early-phase clinical trials of adoptive cell immunotherapy.
Wages NA; Fadul CE
Clin Trials; 2020 Apr; 17(2):157-165. PubMed ID: 31856602
[TBL] [Abstract][Full Text] [Related]
3. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
[TBL] [Abstract][Full Text] [Related]
4. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
Du Y; Yin J; Sargent DJ; Mandrekar SJ
J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
[TBL] [Abstract][Full Text] [Related]
5. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
[TBL] [Abstract][Full Text] [Related]
6. Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials.
Wheeler GM; Sweeting MJ; Mander AP
Stat Med; 2017 Jul; 36(16):2499-2513. PubMed ID: 28295513
[TBL] [Abstract][Full Text] [Related]
7. Isotonic design for phase I cancer clinical trials with late-onset toxicities.
Wages NA; Braun TM; Conaway MR
J Biopharm Stat; 2023 May; 33(3):357-370. PubMed ID: 36606874
[TBL] [Abstract][Full Text] [Related]
8. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.
Postel-Vinay S; Collette L; Paoletti X; Rizzo E; Massard C; Olmos D; Fowst C; Levy B; Mancini P; Lacombe D; Ivy P; Seymour L; Le Tourneau C; Siu LL; Kaye SB; Verweij J; Soria JC
Eur J Cancer; 2014 Aug; 50(12):2040-9. PubMed ID: 24880774
[TBL] [Abstract][Full Text] [Related]
9. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
[TBL] [Abstract][Full Text] [Related]
10. A novel framework of Bayesian optimal interval design for phase I trials with late-onset toxicities.
Zhou H; Chen C; Sun L; Zeng Z
Contemp Clin Trials; 2021 Jun; 105():106404. PubMed ID: 33862287
[TBL] [Abstract][Full Text] [Related]
11. phase1RMD: An R package for repeated measures dose-finding designs with novel toxicity and efficacy endpoints.
Yin J; Du Y; Qin R; Shen S; Mandrekar S
PLoS One; 2021; 16(9):e0256391. PubMed ID: 34473708
[TBL] [Abstract][Full Text] [Related]
12. Range and trend of expected toxicity level (ETL) in standard A + B designs: a report from the Children's Oncology Group.
Chen Z; Krailo MD; Sun J; Azen SP;
Contemp Clin Trials; 2009 Mar; 30(2):123-8. PubMed ID: 19000782
[TBL] [Abstract][Full Text] [Related]
13. Dose-finding designs for trials of molecularly targeted agents and immunotherapies.
Chiuzan C; Shtaynberger J; Manji GA; Duong JK; Schwartz GK; Ivanova A; Lee SM
J Biopharm Stat; 2017; 27(3):477-494. PubMed ID: 28166468
[TBL] [Abstract][Full Text] [Related]
14. A hybrid design for dose-finding oncology clinical trials.
Liao JJZ; Zhou F; Zhou H; Petruzzelli L; Hou K; Asatiani E
Int J Cancer; 2022 Nov; 151(9):1602-1610. PubMed ID: 35802470
[TBL] [Abstract][Full Text] [Related]
15. Towards using a full spectrum of early clinical trial data: a retrospective analysis to compare potential longitudinal categorical models for molecular targeted therapies in oncology.
Colin P; Micallef S; Delattre M; Mancini P; Parent E
Stat Med; 2015 Sep; 34(22):2999-3016. PubMed ID: 26059319
[TBL] [Abstract][Full Text] [Related]
16. Dose optimization for cancer treatments with considerations for late-onset toxicities.
Biard L; Andrillon A; Silva RB; Lee SM
Clin Trials; 2024 Jun; 21(3):322-330. PubMed ID: 38591582
[TBL] [Abstract][Full Text] [Related]
17. Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information.
Zhang Y; Kutner M; Chen Z
Biom J; 2021 Oct; 63(7):1476-1492. PubMed ID: 33969525
[TBL] [Abstract][Full Text] [Related]
18. Implementing and assessing Bayesian response-adaptive randomisation for backfilling in dose-finding trials.
Pin L; Villar SS; Dehbi HM
Contemp Clin Trials; 2024 Jul; 142():107567. PubMed ID: 38729298
[TBL] [Abstract][Full Text] [Related]
19. Dose-finding designs for cumulative toxicities using multiple constraints.
Lee SM; Ursino M; Cheung YK; Zohar S
Biostatistics; 2019 Jan; 20(1):17-29. PubMed ID: 29140414
[TBL] [Abstract][Full Text] [Related]
20. A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.
Yin J; Qin R; Ezzalfani M; Sargent DJ; Mandrekar SJ
Stat Med; 2017 Jan; 36(1):67-80. PubMed ID: 27633877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
